Header Logo

Connection

RACHELLE DOODY to Aged

Back to Details
This is a "connection" page, showing publications RACHELLE DOODY has written about Aged.
RACHELLE DOODY
Connection Strength
2.126
Aged
  1. Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 01; 82(1):19-29.
    View in: PubMed
    Score: 0.069
  2. Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). J Alzheimers Dis. 2025 Jan; 103(2):528-541.
    View in: PubMed
    Score: 0.068
  3. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. J Prev Alzheimers Dis. 2024; 11(3):537-548.
    View in: PubMed
    Score: 0.064
  4. Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD). J Alzheimers Dis. 2024; 101(1):353-367.
    View in: PubMed
    Score: 0.064
  5. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022 11 01; 79(11):1113-1121.
    View in: PubMed
    Score: 0.059
  6. Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. J Prev Alzheimers Dis. 2021; 8(1):3-6.
    View in: PubMed
    Score: 0.052
  7. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population. J Prev Alzheimers Dis. 2021; 8(2):151-160.
    View in: PubMed
    Score: 0.052
  8. Different Cognitive Profiles Are Associated with Progression Rate and Age at Death in Probable Alzheimer's Disease. J Alzheimers Dis. 2021; 80(2):735-747.
    View in: PubMed
    Score: 0.052
  9. Longitudinal Sensitivity of Alzheimer's Disease Severity Staging. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec; 35:1533317520918719.
    View in: PubMed
    Score: 0.049
  10. Gantenerumab reduces amyloid-? plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019 12 12; 11(1):101.
    View in: PubMed
    Score: 0.048
  11. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial. J Alzheimers Dis. 2017; 56(4):1495-1504.
    View in: PubMed
    Score: 0.039
  12. Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease. PLoS One. 2016; 11(8):e0160671.
    View in: PubMed
    Score: 0.038
  13. Prevalence and correlates of cognitive asymmetry in a large sample of Alzheimer's disease patients. J Clin Exp Neuropsychol. 2016; 38(5):516-26.
    View in: PubMed
    Score: 0.037
  14. How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond? Clin Neuropsychol. 2015; 29(7):1002-9.
    View in: PubMed
    Score: 0.037
  15. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. CNS Spectr. 2016 12; 21(6):450-459.
    View in: PubMed
    Score: 0.036
  16. Adding delayed recall to the ADAS-cog improves measurement precision in mild Alzheimer's disease: Implications for predicting instrumental activities of daily living. Psychol Assess. 2015 Dec; 27(4):1234-40.
    View in: PubMed
    Score: 0.035
  17. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21.
    View in: PubMed
    Score: 0.032
  18. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50.
    View in: PubMed
    Score: 0.031
  19. Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimers Dis. 2013; 34(2):449-56.
    View in: PubMed
    Score: 0.030
  20. Factor structure of the Geriatric Depression Scale and relationships with cognition and function in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 34(5-6):360-72.
    View in: PubMed
    Score: 0.030
  21. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement. 2013 May; 9(3):338-45.
    View in: PubMed
    Score: 0.029
  22. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012; 33(2-3):164-73.
    View in: PubMed
    Score: 0.029
  23. Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores. Alzheimers Dement. 2012 Jul; 8(4):288-94.
    View in: PubMed
    Score: 0.028
  24. Item response theory reveals variability of functional impairment within clinical dementia rating scale stages. Dement Geriatr Cogn Disord. 2011; 32(5):362-6.
    View in: PubMed
    Score: 0.028
  25. Greater precision when measuring dementia severity: establishing item parameters for the Clinical Dementia Rating Scale. Dement Geriatr Cogn Disord. 2012; 34(2):128-34.
    View in: PubMed
    Score: 0.028
  26. Dementia staging across three different methods. Dement Geriatr Cogn Disord. 2011; 31(5):328-33.
    View in: PubMed
    Score: 0.027
  27. Apolipoprotein E polymorphism and age at onset of Alzheimer's disease in a quadriethnic sample. Dement Geriatr Cogn Disord. 2010; 30(6):486-91.
    View in: PubMed
    Score: 0.026
  28. Identifying amnestic mild cognitive impairment in primary care: a feasibility study. Clin Drug Investig. 2011; 31(7):483-91.
    View in: PubMed
    Score: 0.026
  29. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010 Mar; 25(2):155-9.
    View in: PubMed
    Score: 0.024
  30. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease? Dement Geriatr Cogn Disord. 2009; 28(1):63-9.
    View in: PubMed
    Score: 0.024
  31. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Recruitment of participants for Alzheimer's disease clinical trials: the role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors. Alzheimers Dement. 2009 Mar; 5(2):122-4.
    View in: PubMed
    Score: 0.023
  32. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease. Alzheimers Dement. 2009 Mar; 5(2):133-6.
    View in: PubMed
    Score: 0.023
  33. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009 May 05; 72(18):1555-61.
    View in: PubMed
    Score: 0.023
  34. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19; 372(9634):207-15.
    View in: PubMed
    Score: 0.022
  35. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008; 25(2):163-74.
    View in: PubMed
    Score: 0.021
  36. Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord. 2007; 24(6):476-82.
    View in: PubMed
    Score: 0.021
  37. Is functional decline necessary for a diagnosis of Alzheimer's disease? Dement Geriatr Cogn Disord. 2007; 24(5):375-9.
    View in: PubMed
    Score: 0.021
  38. Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type. Arch Clin Neuropsychol. 2007 Jan; 22(1):99-107.
    View in: PubMed
    Score: 0.020
  39. Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. Dement Geriatr Cogn Disord. 2005; 20(2-3):198-208.
    View in: PubMed
    Score: 0.018
  40. Refining treatment guidelines in Alzheimer's disease. Geriatrics. 2005 Jun; Suppl:14-20.
    View in: PubMed
    Score: 0.018
  41. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol. 2005 Mar; 62(3):454-9.
    View in: PubMed
    Score: 0.017
  42. A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data. Parkinsonism Relat Disord. 2025 Mar; 132:107257.
    View in: PubMed
    Score: 0.017
  43. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec; 30(12):3669-3675.
    View in: PubMed
    Score: 0.017
  44. The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls. Alzheimer Dis Assoc Disord. 2004 Oct-Dec; 18(4):236-40.
    View in: PubMed
    Score: 0.017
  45. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2004; 18(2):227-32.
    View in: PubMed
    Score: 0.017
  46. WAIS-R factor structure in Alzheimer's disease patients: a comparison of alternative models and an assessment of their generalizability. Psychol Aging. 2003 Dec; 18(4):836-43.
    View in: PubMed
    Score: 0.016
  47. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. N Engl J Med. 2023 Nov 16; 389(20):1862-1876.
    View in: PubMed
    Score: 0.016
  48. A method for estimating duration of illness in Alzheimer's disease. Dement Geriatr Cogn Disord. 2004; 17(1-2):1-4.
    View in: PubMed
    Score: 0.016
  49. Effects of blood pressure on neuropsychological functioning in Alzheimer's disease. Arch Clin Neuropsychol. 2003 Jan; 18(1):19-32.
    View in: PubMed
    Score: 0.015
  50. Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. J Alzheimers Dis. 2022; 85(1):31-45.
    View in: PubMed
    Score: 0.014
  51. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Jul-Aug; 12(4):295-300.
    View in: PubMed
    Score: 0.013
  52. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):427-33.
    View in: PubMed
    Score: 0.013
  53. A method for estimating progression rates in Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):449-54.
    View in: PubMed
    Score: 0.013
  54. Chinese Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer's Disease. J Prev Alzheimers Dis. 2021; 8(2):175-180.
    View in: PubMed
    Score: 0.013
  55. Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. Alzheimer Dis Assoc Disord. 2001 Jan-Mar; 15(1):1-9.
    View in: PubMed
    Score: 0.013
  56. Does APO epsilon4 correlate with MRI changes in Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2000 Nov; 69(5):668-71.
    View in: PubMed
    Score: 0.013
  57. The influence of handedness on the clinical presentation and neuropsychology of Alzheimer disease. Arch Neurol. 1999 Sep; 56(9):1133-7.
    View in: PubMed
    Score: 0.012
  58. Clinical benefits of a new piperidine-class AChE inhibitor. Eur Neuropsychopharmacol. 1999 Apr; 9 Suppl 2:S69-77.
    View in: PubMed
    Score: 0.012
  59. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A?, tau, immunity and lipid processing. Nat Genet. 2019 03; 51(3):414-430.
    View in: PubMed
    Score: 0.011
  60. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology. 1999; 45 Suppl 1:23-32.
    View in: PubMed
    Score: 0.011
  61. Baylor profound mental status examination: a brief staging measure for profoundly demented Alzheimer disease patients. Alzheimer Dis Assoc Disord. 1999 Jan; 13(1):53-9.
    View in: PubMed
    Score: 0.011
  62. Alzheimer disease-related activities in China: a report from the International Working Group on the Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1998 Dec; 12(4):263-5.
    View in: PubMed
    Score: 0.011
  63. Statistical Model of Dynamic Markers of the Alzheimer's Pathological Cascade. J Gerontol B Psychol Sci Soc Sci. 2018 08 14; 73(6):964-973.
    View in: PubMed
    Score: 0.011
  64. Neuropsychological asymmetry in Alzheimer's disease: verbal versus visuoconstructional deficits across stages of dementia. J Int Neuropsychol Soc. 1997 Sep; 3(5):420-7.
    View in: PubMed
    Score: 0.010
  65. Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data. J Alzheimers Dis. 2017; 58(2):361-371.
    View in: PubMed
    Score: 0.010
  66. Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017; 58(4):1217-1228.
    View in: PubMed
    Score: 0.010
  67. Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1997; 9(1):68-74.
    View in: PubMed
    Score: 0.010
  68. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurol. 2016 Jun 09; 16:89.
    View in: PubMed
    Score: 0.009
  69. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology. 1996 Mar; 46(3):720-6.
    View in: PubMed
    Score: 0.009
  70. Hemispheric asymmetry in Alzheimer's disease is apparent in motor functioning. J Clin Exp Neuropsychol. 1996 Feb; 18(1):110-21.
    View in: PubMed
    Score: 0.009
  71. Validation of the Spanish version of the Baylor Profound Mental Status Examination. J Alzheimers Dis. 2016; 49(1):73-8.
    View in: PubMed
    Score: 0.009
  72. Clinical variables associated with psychosis in Alzheimer's disease. Am J Psychiatry. 1995 Sep; 152(9):1377-9.
    View in: PubMed
    Score: 0.009
  73. Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase. Alzheimers Dement. 2016 Jan; 12(1):75-84.
    View in: PubMed
    Score: 0.009
  74. Positive and negative neuropsychiatric features in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1995; 7(1):54-60.
    View in: PubMed
    Score: 0.009
  75. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
    View in: PubMed
    Score: 0.008
  76. Ordered subset analysis of copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis. 2014; 41(4):1063-71.
    View in: PubMed
    Score: 0.008
  77. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44.
    View in: PubMed
    Score: 0.008
  78. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013 Jun 06; 13:56.
    View in: PubMed
    Score: 0.008
  79. The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results. BMC Neurol. 2013 Jan 10; 13:3.
    View in: PubMed
    Score: 0.007
  80. Molecular neuropsychology: creation of test-specific blood biomarker algorithms. Dement Geriatr Cogn Disord. 2014; 37(1-2):45-57.
    View in: PubMed
    Score: 0.007
  81. Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis. 2013; 33(2):517-23.
    View in: PubMed
    Score: 0.007
  82. Integrated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease. Transl Psychiatry. 2012 Nov 20; 2:e192.
    View in: PubMed
    Score: 0.007
  83. The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992 Sep; 55(9):806-10.
    View in: PubMed
    Score: 0.007
  84. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90.
    View in: PubMed
    Score: 0.007
  85. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One. 2011; 6(12):e28092.
    View in: PubMed
    Score: 0.007
  86. A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord. 2011; 32(1):55-62.
    View in: PubMed
    Score: 0.007
  87. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis. 2011; 27(2):259-69.
    View in: PubMed
    Score: 0.007
  88. Spasmodic dysphonia associated with palatal myoclonus. Ear Nose Throat J. 1990 Dec; 69(12):829-32.
    View in: PubMed
    Score: 0.006
  89. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010 Sep; 67(9):1077-81.
    View in: PubMed
    Score: 0.006
  90. Causes of aggressive behavior in patients with dementia. J Clin Psychiatry. 2010 Sep; 71(9):1145-52.
    View in: PubMed
    Score: 0.006
  91. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010 Mar 23; 74(12):956-64.
    View in: PubMed
    Score: 0.006
  92. Consequences of aggressive behavior in patients with dementia. J Neuropsychiatry Clin Neurosci. 2010; 22(1):40-7.
    View in: PubMed
    Score: 0.006
  93. Vitamin E use is associated with improved survival in an Alzheimer's disease cohort. Dement Geriatr Cogn Disord. 2009; 28(6):536-40.
    View in: PubMed
    Score: 0.006
  94. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 Dec 15; 73(24):2061-70.
    View in: PubMed
    Score: 0.006
  95. Mental status assessment of insight and judgment. Clin Geriatr Med. 1989 Aug; 5(3):477-98.
    View in: PubMed
    Score: 0.006
  96. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92.
    View in: PubMed
    Score: 0.006
  97. Korean version of the Baylor Profound Mental Status Examination: a brief staging measure for patients with severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(1):69-75.
    View in: PubMed
    Score: 0.006
  98. Exploring self-neglect in older adults: preliminary findings of the self-neglect severity scale and next steps. J Am Geriatr Soc. 2008 Nov; 56 Suppl 2:S253-60.
    View in: PubMed
    Score: 0.006
  99. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008 Aug; 65(8):1091-5.
    View in: PubMed
    Score: 0.005
  100. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008 Mar; 4(2):145-53.
    View in: PubMed
    Score: 0.005
  101. Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. J Psychiatr Res. 2008 Oct; 42(14):1203-12.
    View in: PubMed
    Score: 0.005
  102. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007 Oct 16; 69(16):1622-34.
    View in: PubMed
    Score: 0.005
  103. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul 31; 69(5):459-69.
    View in: PubMed
    Score: 0.005
  104. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008 Sep; 29(9):1285-95.
    View in: PubMed
    Score: 0.005
  105. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S124-38.
    View in: PubMed
    Score: 0.005
  106. Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 22(4):367-77.
    View in: PubMed
    Score: 0.005
  107. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006 Sep-Oct; 10(5):417-29.
    View in: PubMed
    Score: 0.005
  108. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006 Jan; 63(1):49-54.
    View in: PubMed
    Score: 0.005
  109. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother. 2006; 4 Suppl A:S9-S24; quiz S25-S28.
    View in: PubMed
    Score: 0.005
  110. The making of a self-neglect severity scale. J Elder Abuse Negl. 2006; 18(4):13-23.
    View in: PubMed
    Score: 0.005
  111. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):178-83.
    View in: PubMed
    Score: 0.005
  112. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord. 2005; 20(6):338-44.
    View in: PubMed
    Score: 0.005
  113. Self-reported awareness of performance in dementia. Brain Res Cogn Brain Res. 2005 Sep; 25(1):144-52.
    View in: PubMed
    Score: 0.004
  114. Factors affecting deficit awareness in persons with dementia. Dement Geriatr Cogn Disord. 2005; 20(2-3):133-9.
    View in: PubMed
    Score: 0.004
  115. Accuracy of self-reported depression in persons with dementia. J Am Geriatr Soc. 2005 Mar; 53(3):389-96.
    View in: PubMed
    Score: 0.004
  116. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66.
    View in: PubMed
    Score: 0.004
  117. Dementia Deficits Scale. Rating self-awareness of deficits. Alzheimer Dis Assoc Disord. 2004 Jan-Mar; 18(1):22-31.
    View in: PubMed
    Score: 0.004
  118. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003 Dec; 60(12):1696-702.
    View in: PubMed
    Score: 0.004
  119. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
    View in: PubMed
    Score: 0.004
  120. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 03; 348(14):1333-41.
    View in: PubMed
    Score: 0.004
  121. A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology. 2002 Feb 12; 58(3):433-7.
    View in: PubMed
    Score: 0.004
  122. Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases. Dement Geriatr Cogn Disord. 2002; 13(1):8-12.
    View in: PubMed
    Score: 0.003
  123. Current concepts in mild cognitive impairment. Arch Neurol. 2001 Dec; 58(12):1985-92.
    View in: PubMed
    Score: 0.003
  124. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001 Aug 14; 57(3):481-8.
    View in: PubMed
    Score: 0.003
  125. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000 May; 10(3):195-203.
    View in: PubMed
    Score: 0.003
  126. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000 Feb 23; 283(8):1007-15.
    View in: PubMed
    Score: 0.003
  127. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11; 158(9):1021-31.
    View in: PubMed
    Score: 0.003
  128. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan; 50(1):136-45.
    View in: PubMed
    Score: 0.003
  129. Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology. 1997 Jul; 49(1):44-50.
    View in: PubMed
    Score: 0.003
  130. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease. Neurology. 1997 Jul; 49(1):70-5.
    View in: PubMed
    Score: 0.003
  131. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S22-32.
    View in: PubMed
    Score: 0.002
  132. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 3:8-18.
    View in: PubMed
    Score: 0.002
  133. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 3:46-9.
    View in: PubMed
    Score: 0.002
  134. Establishing the limits of the Mini-Mental State. Examination of 'subtests'. Arch Neurol. 1992 Jan; 49(1):87-92.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.